Seeking Alpha

Sarepta (SRPT) +11.5% to $12.02 after a positive weekend article in Barrons about the company's...

Sarepta (SRPT) +11.5% to $12.02 after a positive weekend article in Barrons about the company's Eteplirsen treatment for Duchenne muscular dystrophy, which could receive expedited approval from the FDA if its Phase IIb trials are as strong as earlier studies. One analyst has a price target of $16 and reckons peak sales could hit $600M; however, writing on The Street, Nathan Sadeghi-Nejad remains cautious.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|